Kailera Therapeutics is developing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for clinical obesity, chronic weight management and related conditions.
Products & media
An investigational once-weekly injectable GLP-1/GIP receptor dual agonist being studied for obesity in global Phase 3 trials.
An investigational once-daily oral small-molecule GLP-1 receptor agonist being evaluated in clinical trials for obesity.
An investigational once-daily oral tablet formulation of the GLP-1/GIP receptor dual agonist ribupatide being developed for obesity.
An investigational once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist being developed for obesity treatment.
Jobs
See all jobs for Kailera Therapeutics here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
$600M
$400M
